Zobrazeno 1 - 10 of 17 pro vyhledávání: '"Atul Khandwala"'
1
A Double Blind, Randomized, Placebo-Controlled Phase Ii Study to Assess The Safety and Efficacy of Orally Administered Sp-303 for The Symptomatic Treatment of Diarrhea in Patients With AIDS
Autor: Mark Holodniy, Jamey M Schmidt, James E Pennington, Mark Mistal, Steven B. Porter, Atul Khandwala, Johannes Koch
Publikováno v: American Journal of Gastroenterology. 94:3267-3273
The aim of this study was to investigate the safety and effectiveness of orally administered SP-303 in patients with AIDS and diarrhea.This is a multicenter, phase II, randomized, double blind, placebo-controlled study. HIV-positive subjects with a h
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09ea2ee729bd9d834f8bc2a2eec1d184
https://doi.org/10.1111/j.1572-0241.1999.01535.x
Zobrazit plný text záznamu
2
A double-blind study of topically applied 5% amlexanox in the treatment of aphthous ulcers
Autor: Robert O. Greer, Atul Khandwala, Timothy Juarez, James E. Lindenmuth
Publikováno v: Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 51(3)
A double-blind trial of amlexanox (C16H14N2O4) was carried out in 32 patients with recurrent oral aphthous ulcerations. During the treatment period, which lasted for 3 days, patients received either placebo topical paste or 5% amlexanox paste. The pa
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a471d74a1d4f835614b2857f5fbe2c58
https://pubmed.ncbi.nlm.nih.gov/8445464
Zobrazit plný text záznamu
3
REV 2871 (CHBZ): A potent antiallergic agent with a novel mechanism of action
Autor: Atul Khandwala, Stephen M. Coutts, Ira Weinryb
Publikováno v: Biochemical Pharmacology. 36:673-682
REV 2871 (CHBZ) was taken up by rat mast cells and human leukocytes in a specific and saturable manner. The compound can be hydrolyzed by a granule-associated enzyme in the mast cell to an ionic metabolite (REV 3579) whose in vitro profile is identic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e2fe6bb239b4964fdbe83f9723bbfa87
https://doi.org/10.1016/0006-2952(87)90718-0
Zobrazit plný text záznamu
4
Perspectives on the in vitro evaluation of anti-anaphylactic agents
Autor: Stephen M. Coutts, Ira Weinryb, Atul Khandwala
Publikováno v: Drug Development Research. 3:213-219
In vitro models of anaphylaxis such as the release of mediators from the mast cell can do more than identify compounds with intrinsic anti-allergic activity; they have the potential for development of a detailed profile of activity that may be compar
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::861a3a82c5ae071da564f3e808f18383
https://doi.org/10.1002/ddr.430030303
Zobrazit plný text záznamu
5
REV 2871 (CHBZ): A potent antiallergic agent with a novel mechanism of action
Autor: Howard Jones, Ira Weinryb, Theaddeus Pruss, Atul Khandwala, Stephen M. Coutts, Edward S. Neiss
Publikováno v: Biochemical Pharmacology. 36:663-672
REV 2871 (CHBZ) and its putative metabolite REV 3579-Z (also designated in the literature as RHC 3579-Z) were shown to be potent and orally effective inhibitors of passive cutaneous anaphylaxis (PCA) in the rat (ED 50 = 12 mg/kg). The activity profil
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::151f9012b0d3873e99224c9c266b7a2b
https://doi.org/10.1016/0006-2952(87)90717-9
Zobrazit plný text záznamu
6
Celiprolol
Autor: Grebow P, Wong L, Pruss Tp, Atul Khandwala, Wolf Ps
Publikováno v: Journal of Cardiovascular Pharmacology. 8:S29-S32
Celiprolol HC1 is a new cardioselective beta-blocker with properties which may make it the next advance in the evolution of this class of compounds. Its cardioselectivity has been demonstrated both in vitro and in vivo, with an intravenous potency eq
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56b2eb2dc4b1d737797fb36c5843cac7
https://doi.org/10.1097/00005344-198608004-00005
Zobrazit plný text záznamu
7
Synthesis and antiallergic activities of 1,3-oxazolo[4,5-h]quinolines
Autor: John H. Musser, S. Sciortino, Mitchell J. Leibowitz, P. Sonnino-Goldman, Kevin Bailey, Atul Khandwala, Howard Jones, Stephen M. Coutts, Edward S. Neiss, P. S. Wolf
Publikováno v: Journal of Medicinal Chemistry. 28:1255-1259
A series of new 1,3-oxazolo[4,5-h]quinolines has been prepared. These compounds were tested as inhibitors of antigen-induced release of histamine (AIR) in vitro from rat peritoneal mast cells (RMC) and as inhibitors of IgE-mediated passive cutaneous
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfdb8b48978971d1a5c88c45cb6c0d96
https://doi.org/10.1021/jm00147a023
Zobrazit plný text záznamu
10
REV 2871 (CHBZ): A novel inhibitor of histamine release
Autor: Shoupe T Scott, Atul Khandwala, Ira Weinryb, Lewis J. Klunk, Stephen M. Coutts, John H. Musser
Publikováno v: Agents and Actions. 18:318-324
CHBZ is a novel, non-disodium cromoglycate (DSCG)-like, antiallergic drug in vitro. Whereas DSCG loses antisecretory activity with increasing time of preincubation with rat mast cells (RMC) before antigen challenge, and does not inhibit non-immunolog
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddc91ece49ca934e71125bab04a5e992
https://doi.org/10.1007/bf01964991
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje